(Drug Name) (Drug Form) (Drug Strength)
show timeout overlay link

Your Session Is About to Expire

This online session is about to expire due to inactivity. Click Continue to return to page.

  • myWeekly Ad

ESBRIET: Oral capsule (267mg)

Also see:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics

Visit Drug Summary Page
Drug Image file default-drug-image.png


What is this Medicine?

PIRFENIDONE (peer FEH nih done) is used to treat idiopathic pulmonary fibrosis.

In-Depth Information

Esbriet 267mg Capsule

NDC: 641160121
  • Prescription Required
  • Not a Controlled Drug
    (CSA Schedule)
  • FDA Approved




FDA approved for the following conditions:
Pulmonary Fibrosis

Storage Information
Store at 77 degrees F; excursions permitted to 59-86 degrees F
Esbriet 267mg Capsule

Reported Side Effects for Esbriet 267mg Capsule

Elevated Hepatic Enzymes Incidence:
3.7%*
Severity: MODERATE
Onset: DELAYED
Chest Pain Incidence:
5.0%*
Severity: MODERATE
Onset: EARLY
Metallic Taste Incidence:
6.0%*
Severity: MILD
Onset: EARLY
Weakness Incidence:
6.0%*
Severity: MILD
Onset: DELAYED
Itching Incidence:
8.0%*
Severity: MILD
Onset: RAPID
Photosensitivity Incidence:
9.0%*
Severity: MILD
Onset: DELAYED
Inability To Sleep Incidence:
10.0%*
Severity: MILD
Onset: EARLY
Weight Loss Incidence:
10.0%*
Severity: MILD
Onset: DELAYED
Joint Pain Incidence:
10.0%*
Severity: MILD
Onset: DELAYED
Sinus Infection Incidence:
11.0%*
Severity: MILD
Onset: DELAYED
Heartburn Incidence:
11.0%*
Severity: MILD
Onset: DELAYED
Vomiting Incidence:
13.0%*
Severity: MILD
Onset: EARLY
Decreased Appetite Incidence:
13.0%*
Severity: MILD
Onset: DELAYED
Lightheadedness Incidence:
18.0%*
Severity: MILD
Onset: EARLY
Upset Stomach Incidence:
19.0%*
Severity: MILD
Onset: EARLY
Headache Incidence:
22.0%*
Severity: MILD
Onset: EARLY
Stomach Pain Incidence:
24.0%*
Severity: MILD
Onset: EARLY
Tired Incidence:
26.0%*
Severity: MILD
Onset: EARLY
Loose Stools Incidence:
26.0%*
Severity: MILD
Onset: EARLY
Infection Incidence:
27.0%*
Severity: MILD
Onset: DELAYED
Skin Rash Incidence:
30.0%*
Severity: MILD
Onset: EARLY
Upset Stomach Incidence:
36.0%*
Severity: MILD
Onset: EARLY
*This is an approximate aggregated range of reported side effects from clinical studies performed on this drug. Your experience with this drug may be different.
Pregnancy & Lactation Information
FIRST Trimester

Class C - Animal studies have shown an adverse effect and there are no adequate and well-controlled studies in pregnant women. OR No animal studies have been conducted and there are no adequate and well-controlled studies in pregnant women.

SECOND Trimester

Class C - Animal studies have shown an adverse effect and there are no adequate and well-controlled studies in pregnant women. OR No animal studies have been conducted and there are no adequate and well-controlled studies in pregnant women.

THIRD Trimester

Class C - Animal studies have shown an adverse effect and there are no adequate and well-controlled studies in pregnant women. OR No animal studies have been conducted and there are no adequate and well-controlled studies in pregnant women.

Lactation

Caution - Not enough information is available to rule out harm to infants when this drug is taken by nursing mothers.


Learning More About
Visit the Drug Summary page where you can:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics
Learn More
Patient Experiences with ESBRIET

Be the first to share your experience!

We want to help our customers stay educated about the medications they are taking. Submit your own observations and experiences to benefit others.

Average Scores
Easy to Take 
0 / 5
0 / 5
Works as Intended 
0 / 5
0 / 5
Tolerable 
0 / 5
0 / 5